Coya Therapeutics Completes Merger with Nicoya Health Inc. and Announces $10 Million Series A Financing
The merger and financing, which include conversion of outstanding debt, was led by Allele Capital Partners LLC. Howard Berman, Ph.D., has been appointed as Chief Executive Officer and a member of the Company’s Board of Directors.
Avacta Group Announces AffyXell Secures $7.3 Million In Series A Financing
Avacta Group notes the funds will be used to further develop its pipeline of next generation cell and gene therapies.
ARCH Venture Partners Announces New $1.85 Billion Fund to Create and Fund Early Stage Biotechnology Companies
ARCH Venture Partners will invest Fund XI in early-stage biotechnology companies working on infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging medicines, genomic and biological tools, data sciences, and ways of reimagining diagnostics and therapies.
Vaxess Technologies Awarded NSF and DARPA Funding for Development of mRNA-Based Single-Dose, Refrigeration-Free Vaccine Patch
Vaxess Technologies developers of the MIMIX™ smart release patch, was awarded a grant from the National Science Foundation.
Innodem Neurosciences Receives $6 Mil US Dollars of Financing From Morningside Group
The company reports their mobile software technology is embodied in an application that turns a tablet or a smartphone into a device capable of capturing Eye Movement Biomarkers and Gaze Mapping Biomarkers accurately within minutes in order to assist a clinician's diagnosis.